

Acute myocardial infarction: reperfusion treatment

Flavio Ribichini and William Wijns

Web-only References

- (1) Calif RM. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. *Am Heart J* 1999;138:S12-S15
- (2) Barron HV, Bowlby LJ, Breen T, et al for the National Registry of Myocardial Infarction 2 Investigators. Use of reperfusion therapy for acute myocardial infarction in the United States. Data from the National Registry of Myocardial Infarction 2. *Circulation* 1998;97:1150-1156
- (3) Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1993;328:673-679
- (4) Zijlstra F, de Boer MJ, Hoorntje JCA, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. *N Engl J Med* 1993; 328:680-684
- (5) Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. *N Engl J Med* 1993;328:685-691
- (6) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988;2:349-360
- (7) Rawles J, on behalf of the GREAT Study. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). *J Am Coll Cardiol* 1994;23:1-5
- (8) Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith III EE, Weaver WD. 1999 Update. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1999;34:890-911
- (9) Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression. *J Am Coll Cardiol* 1998;32:1687-1694

- (10) Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute myocardial infarction with percutaneous transluminal angioplasty. *Circulation* 1998;98:2377-2382
- (11) Every NR, Parsons LS, Hlatky M, et al for the Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. *N Engl J Med* 1996;335:1253-1260
- (12) Vogt A, Niederer W, Pfafferott C, et al on behalf of the study group of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Direct percutaneous transluminal coronary angioplasty in acute myocardial infarction. Predictors of short-term outcome and the impact of coronary stenting. *Eur Heart J* 1998;19:917-921
- (13) Zijlstra F. Long-term benefit of primary angioplasty compared to thrombolytic therapy for acute myocardial infarction. *Eur Heart J* 2000;21:1487-1489
- (14) Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. *N Engl J Med* 1999;341:1949-1956
- (15) Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 2002;346:957-966
- (16) Neumann FJ, Kastrati A, Schmitt C, et al Effects of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis after the placement of coronary stents following acute myocardial infarction. *J Am Coll Cardiol* 2000;35:915-921
- (17) Kennedy JW, Stadius ML. Combined thrombolytic therapy and platelet glycoprotein IIb/IIIa inhibitor therapy for acute myocardial infarction. Will the pharmacological therapy ever equal primary angioplasty? *Circulation* 1999;99:2714-2716
- (18) Ohman EM, Kleiman NS, Gacioch G, et al for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. *Circulation* 1997;95:846-854
- (19) Van de Werf F, Neuhaus KL. Late-breaking clinical trials II: coronary artery disease. Assessment of the safety and efficacy of a new thrombolytic: TNK-tPA Trial (ASSENT-2), and A phase III Trial of novel thrombolytic lanoteplase (nPA): In-Time-II. *J Am Coll Cardiol* 1999;34:4-5
- (20) Califf RM. Ten years of benefit from a one-hour intervention. *Circulation* 1998;98:264-2651

- 21) Blankenship JC, Almqvist AK. Cardiovascular complications of thrombolytic therapy in patients with a mistaken diagnosis of acute myocardial infarction. *J Am Coll Cardiol* 1989;14:1579-1582
- 22) Wilcox RG, Olsson CG, Skene AM, Von Der Lippe G, Jensen G, Hampton JR. Trial of tissue plasminogen activator for the mortality reduction in acute myocardial infarction. AngloScandinavian Study of Early Thrombolysis (ASSET). *Lancet* 1988;2:525-530
- (23) Liem AY, Van'T Hof AWJ, Hoorntje JCA, et al. Influence of treatment delay on infarct size and clinical outcome inpatients with acute myocardial infarction treated with primary angioplasty. *J Am Coll Cardiol* 1998;32:629-63
- (24) Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1998;32:1312-1319
- (25) Berger PB, Ellis SG, Holmes DR, et al for the GUSTO-II Investigators. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Results from the Global Use of Strategies to Open Occluded Arteries in 47 Acute Coronary Syndromes (GUSTO-IIb) Trial. *Circulation* 1999;100:14-20
- (26) Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early, intermediate and late presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. *Eur Heart J* 2002;23:550-557
- (27) Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. *Lancet* 1994; 343:311-322
- (28) Zijlstra F. Acute myocardial infarction: primary angioplasty. *Heart* 2001;85:705-709
- (29) Nunn CM, O'Neill WW, Rothbaum D, et al for the Primary Angioplasty in Myocardial Infarction I Study Group. Long-term outcome after primary angioplasty: report from the Primary Angioplasty in Myocardial Infarction (PAMI-I) Trial. *J Am Coll Cardiol* 1999;33:640-646
- (30) Birkhead JS. Thrombolytic treatment for myocardial infarction: an examination of practice in 39 United Kingdom hospitals. Myocardial Infarction Audit Group. *Heart* 1997;78:28-33
- (31) Boyle RM. Immediate angioplasty in the United Kingdom. The time has not yet come. *International Roundup. BHJ* 1995;73:413-414

- (32) Zahn R, Schiele R, Seidl K, et al. Spectrum of reperfusion strategies and factors influencing the use of primary angioplasty in patients with acute myocardial infarction admitted to hospitals with the facilities to perform primary angioplasty. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. *Heart* 1999;82:420-425
- (33) Wagner S, Schneider S, Schiele R, et al. Acute myocardial infarction in Germany between 1996 and 1998 therapy and intrahospital course. Results of the Myocardial Infarction Registry (MIR) in Germany. *Z Kardiol* 1999;88:857-867
- (34) Monassier JP, Hanania G, Khalife K, et al. Therapeutic strategies in acute myocardial infarction. Results of the STIM 93 Registry. *Arch Mal Coeur Vaiss* 1996;89:281-289
- (35) Danchin N, Vaur L, Genes N, et al. Management of acute myocardial infarction in intensive care units in 1995: a nationwide French survey of practice and early hospital results. *J Am Coll Cardiol* 1997;30:1598-1605
- (36) Juliard JM, Himbert D, Aubry P, et al. Orientated management towards reperfusion in the acute phase of myocardial infarction. Results in a cohort of 700 consecutive patients. *Arch Mal Coeur Vaiss* 1997;90:337-343
- (37) Behar S. Use of thrombolysis for myocardial infarction in Israel. *Harefuah* 1992;122:753-756
- (38) Reikvam A, Ketley D. Thrombolytic eligibility in acute myocardial infarction patients admitted to Norwegian hospitals. *Int J Cardiol* 1997;61:79-83
- (39) Herlitz J, Abrahamsson P, Dellborg M, et al. Long-term survival after development of acute myocardial infarction has improved after a more widespread use of thrombolysis and aspirin. *Cardiology* 1999;91:250-255
- (40) Bosch X, Sambola A, Aros F, et al. Use of thrombolytic treatment in patients with acute myocardial infarction in Spain. Observations from the PRIAMHO Study. *Rev Esp Cardiol* 2000;53:490-501
- (41) Cabades A, Echanove I, Cebrian J, et al. The characteristics, management and prognosis of the acute myocardial infarct patient in the Valencian Community in 1995: the results of the PRIMVAC Registry. *Rev Esp Cardiol* 1999;52:123-133
- (42) French JK, Williams BF, Hart HH, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. *BMJ* 1996;312:1637-1641
- (43) Hooi H. Review of Emergency department thrombolytic therapy and changes in inpatient mortality of acute myocardial infarction on NSW Central Coast 1986 to 1994-96. *Aust N Z Med* 1999;29:505-511

(44) Van de Werf F, Topol EJ, Lee KL, *et al.* Variations in the patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO Trial. *JAMA* 1995;**273**:1586-1591

(45) Zahn R, Schuster S, Scheile R, *et al* for the MITRA Study Group. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. *Cathet Cardiovasc Intervent* 1999;**46**:127-133

(46) Aversano T, Aversano LT, Passamani E, *et al.* Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery. *JAMA* 2002;**287**:1943-1951

(47) Ito H, Okamura A, Iwakura K, *et al.* Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. *Circulation* 1996;**93**:1993-1999

(48) Stone GW, Grines CL, Rothbaum D, *et al.* Analysis of the related costs and effectiveness of primary angioplasty compared to tissue plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. *J Am Coll Cardiol* 1997;**29**:901-907

(49) Grines CL, Marsalese DL, Brodie B, *et al.* Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. *J Am Coll Cardiol* 1998;**33**:967-972

(50) Meijer A, Verheugt FWA, Werter CJPJ, *et al.* Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study: results of the APRICOT Study. *Circulation* 1993;**87**:1524-1530

(51) Roberts WC, Buja LM. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction. A study of 107 necropsy patients. *Am J Med* 1972;**52**: 425-443

(52) Murakami T, Mizuno S, Takahashi Y, *et al.* Intracoronary aspiration thrombectomy for acute myocardial infarction. *Am J Cardiol* 1998;**82**:839-844

(53) Loubeyre C, Lefevre T, Louvard Y, *et al.* Outcome after combined reperfusion therapy for acute myocardial infarction, combining pre-hospital thrombolysis with immediate percutaneous coronary intervention and stent. *Eur Heart J* 2001;**22**:1128-1135